These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Integrity of Glycosylation Processing of a Glycan-Depleted Trimeric HIV-1 Immunogen Targeting Key B-Cell Lineages. Behrens AJ, Kumar A, Medina-Ramirez M, Cupo A, Marshall K, Cruz Portillo VM, Harvey DJ, Ozorowski G, Zitzmann N, Wilson IA, Ward AB, Struwe WB, Moore JP, Sanders RW, Crispin M. J Proteome Res; 2018 Mar 02; 17(3):987-999. PubMed ID: 29420040 [Abstract] [Full Text] [Related]
11. A Bispecific Antibody That Simultaneously Recognizes the V2- and V3-Glycan Epitopes of the HIV-1 Envelope Glycoprotein Is Broader and More Potent than Its Parental Antibodies. Davis-Gardner ME, Alfant B, Weber JA, Gardner MR, Farzan M. mBio; 2020 Jan 14; 11(1):. PubMed ID: 31937648 [Abstract] [Full Text] [Related]
12. Stabilizing HIV-1 envelope glycoprotein trimers to induce neutralizing antibodies. Torrents de la Peña A, Sanders RW. Retrovirology; 2018 Sep 12; 15(1):63. PubMed ID: 30208933 [Abstract] [Full Text] [Related]
13. Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope. Schoofs T, Barnes CO, Suh-Toma N, Golijanin J, Schommers P, Gruell H, West AP, Bach F, Lee YE, Nogueira L, Georgiev IS, Bailer RT, Czartoski J, Mascola JR, Seaman MS, McElrath MJ, Doria-Rose NA, Klein F, Nussenzweig MC, Bjorkman PJ. Immunity; 2019 Jun 18; 50(6):1513-1529.e9. PubMed ID: 31126879 [Abstract] [Full Text] [Related]
14. Reduced Potency and Incomplete Neutralization of Broadly Neutralizing Antibodies against Cell-to-Cell Transmission of HIV-1 with Transmitted Founder Envs. Li H, Zony C, Chen P, Chen BK. J Virol; 2017 May 01; 91(9):. PubMed ID: 28148796 [Abstract] [Full Text] [Related]
15. A Rare Mutation in an Infant-Derived HIV-1 Envelope Glycoprotein Alters Interprotomer Stability and Susceptibility to Broadly Neutralizing Antibodies Targeting the Trimer Apex. Mishra N, Sharma S, Dobhal A, Kumar S, Chawla H, Singh R, Das BK, Kabra SK, Lodha R, Luthra K. J Virol; 2020 Sep 15; 94(19):. PubMed ID: 32669335 [Abstract] [Full Text] [Related]
16. HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies. Steichen JM, Kulp DW, Tokatlian T, Escolano A, Dosenovic P, Stanfield RL, McCoy LE, Ozorowski G, Hu X, Kalyuzhniy O, Briney B, Schiffner T, Garces F, Freund NT, Gitlin AD, Menis S, Georgeson E, Kubitz M, Adachi Y, Jones M, Mutafyan AA, Yun DS, Mayer CT, Ward AB, Burton DR, Wilson IA, Irvine DJ, Nussenzweig MC, Schief WR. Immunity; 2016 Sep 20; 45(3):483-496. PubMed ID: 27617678 [Abstract] [Full Text] [Related]
17. Conditional antibody expression to avoid central B cell deletion in humanized HIV-1 vaccine mouse models. Tian M, McGovern K, Cheng HL, Waddicor P, Rieble L, Dao M, Chen Y, Kimble MT, Cantor E, Manfredonia N, Judson R, Chapdelaine-Williams A, Cain DW, Haynes BF, Alt FW. Proc Natl Acad Sci U S A; 2020 Apr 07; 117(14):7929-7940. PubMed ID: 32209668 [Abstract] [Full Text] [Related]